Evidence map›Paper›PMID 39275999›Full record

ArticleProtein science : a publication of the Protein Society2024

Ligand-induced CaMKIIα hub Trp403 flip, hub domain stacking, and modulation of kinase activity.

Dilip Narayanan, Anne Sofie G Larsen, Stine Juul Gauger, Ruth Adafia, Rikke Bartschick Hammershøi, Louise Hamborg, Jesper Bruus-Jensen, Nane Griem-Krey, Christine L Gee, Bente Frølund and 6 more

Abstract read
In one paragraph

Article in Protein science : a publication of the Protein Society, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Dilip NarayananDepartment of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.ORCID 0000-0001-9164-9961
Anne Sofie G LarsenDepartment of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.ORCID 0000-0002-8258-3566
Stine Juul GaugerDepartment of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.ORCID 0000-0002-3017-0962
Ruth AdafiaDepartment of Biochemistry and Molecular Biology, University of Massachusetts, Amherst, Massachusetts, USA.ORCID 0009-0008-4634-6273
Rikke Bartschick HammershøiDepartment of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Louise HamborgDepartment of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.ORCID 0000-0002-8580-9751
Jesper Bruus-JensenDepartment of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Nane Griem-KreyDepartment of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.ORCID 0000-0003-0897-6692
Christine L GeeHHMI, University of California, Berkeley, California, USA.ORCID 0000-0002-2632-6418
Bente FrølundDepartment of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.ORCID 0000-0001-5476-6288
Margaret M StrattonDepartment of Biochemistry and Molecular Biology, University of Massachusetts, Amherst, Massachusetts, USA.ORCID 0000-0003-2686-9022
John KuriyanHHMI, University of California, Berkeley, California, USA.
Jette Sandholm KastrupDepartment of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.ORCID 0000-0003-2654-1510
Annette E LangkildeDepartment of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.ORCID 0000-0003-2467-4205
Petrine WellendorphDepartment of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.ORCID 0000-0002-5455-8013
Sara M Ø SolbakDepartment of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.ORCID 0000-0003-0233-7160

Funding

User Training and OutreachP30GM124169 · NIGMS · UNIVERSITY OF CALIF-LAWRENC BERKELEY LAB · PI Gregory L Hura · 2017 to 2026
$28.6M
Chemistry-Biology Interface Predoctoral Training GrantT32GM139789 · NIGMS · UNIVERSITY OF MASSACHUSETTS AMHERST · PI ERIC Robert STRIETER · 2021 to 2026
$3.4M
Unraveling the molecular events driven by CaMKII in Ca2+-coupled cellsR35GM145376 · NIGMS · UNIVERSITY OF MASSACHUSETTS AMHERST · PI Margaret M Stratton · 2022 to 2026
$2.1M
Danmarks Frie ForskningsfondNIGMS NIH HHS P30 GM124169NIGMS NIH HHS R35 GM145376NIGMS NIH HHS T32 GM139789The Lundbeck FoundationThe Novo Nordisk Foundation
6 · The paper itself

Abstract

γ-Hydroxybutyric acid (GHB) analogs are small molecules that bind competitively to a specific cavity in the oligomeric CaMKIIα hub domain. Binding affects conformation and stability of the hub domain, which may explain the neuroprotective action of some of these compounds. Here, we describe molecular details of interaction of the larger-type GHB analog 2-(6-(4-chlorophenyl)imidazo[1,2-b]pyridazine-2-yl)acetic acid (PIPA). Like smaller-type analogs, PIPA binding to the CaMKIIα hub domain promoted thermal stability. PIPA additionally modulated CaMKIIα activity under sub-maximal CaM concentrations and ultimately led to reduced substrate phosphorylation. A high-resolution X-ray crystal structure of a stabilized CaMKIIα (6x mutant) hub construct revealed details of the binding mode of PIPA, which involved outward placement of tryptophan 403 (Trp403), a central residue in a flexible loop close to the upper hub cavity. Small-angle X-ray scattering (SAXS) solution structures and mass photometry of the CaMKIIα wild-type hub domain in the presence of PIPA revealed a high degree of ordered self-association (stacks of CaMKIIα hub domains). This stacking neither occurred with the smaller compound 3-hydroxycyclopent-1-enecarboxylic acid (HOCPCA), nor when Trp403 was replaced with leucine (W403L). Additionally, CaMKIIα W403L hub was stabilized to a larger extent by PIPA compared to CaMKIIα hub wild type, indicating that loop flexibility is important for holoenzyme stability. Thus, we propose that ligand-induced outward placement of Trp403 by PIPA, which promotes an unforeseen mechanism of hub domain stacking, may be involved in the observed reduction in CaMKIIα kinase activity. Altogether, this sheds new light on allosteric regulation of CaMKIIα activity via the hub domain.

Indexed as

Calcium-Calmodulin-Dependent Protein Kinase Type 2Protein DomainsCrystallography, X-RayHumansLigandsModels, MolecularPhosphorylationPyridazinesScattering, Small AngleTryptophanCalcium-Calmodulin-Dependent Protein Kinase Type 2LigandsPyridazinesTryptophanallosteric regulationCaMKIIαhub domainligandsself‐associationsmall‐angle X‐ray scatteringX‐ray crystallography

Identifiers

PMID39275999
PMCPMC11400628

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.